Aprea Therapeutics (NASDAQ:APRE) Posts Quarterly Earnings Results

Aprea Therapeutics (NASDAQ:APRE) released its quarterly earnings data on Monday. The company reported ($0.32) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.00 million during the quarter. Aprea Therapeutics had a negative net margin of 2,666.46% and a negative return on equity of 88.12%.

Aprea Therapeutics Trading Up 2.7%

Shares of NASDAQ APRE opened at $0.76 on Tuesday. The firm has a market cap of $5.29 million, a PE ratio of -0.35 and a beta of 1.42. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $2.65. The company has a fifty day moving average price of $0.80 and a 200 day moving average price of $1.11.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on APRE shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, January 21st. Wedbush dropped their price target on Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 10th. Zacks Research upgraded Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective (down from $5.00) on shares of Aprea Therapeutics in a research report on Thursday, January 29th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Aprea Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $5.50.

Institutional Trading of Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC acquired a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.67% of Aprea Therapeutics as of its most recent SEC filing. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.